In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CureTech, Ltd.

Latest From CureTech, Ltd.

Otsuka Expands Ocular Gene Therapy Interests Through ShapeTX Deal

Otsuka steps into the ocular gene therapy field through a technology licensing deal worth up to $1.5bn with ShapeTX, which in turn further expands the US firm's global reach following a $3bn collaboration with Roche. 

Gene Therapy Deals

Otsuka Adds To CNS Pipeline With Mindset Acquisition

After a year of R&D collaboration, Otsuka has made a decision to acquire Canadian venture Mindset to further expand its neurological pipeline with new 5-HT2A agonists.  

Commercial Deals

NodThera Looks To Compete In Long-Awaited Inflammasome Field With Parkinson’s Therapy

NodThera is a pioneer in the field of NLRP3 inflammasome inhibitors, and after overcoming drug development setbacks, believes it can compete in a field alongside rivals such as Roche, Novartis and Novo Nordisk.

Inflammation Metabolic Disorders

BioNTech Gets In On ADC Action With DualityBio Licensing Deal

The German biotech is spending some of its pandemic capital on two antibody-drug conjugate candidates from the Chinese firm, including one in Phase II development.

Deals Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register